"The voice for cancer physicians and their patients in Massachusetts."

FDA Approves ZIEXTENZO - A Biosimilar of Neulasta

07 Nov 2019 9:02 AM | Nathan Strunk (Administrator)

The U.S. Food and Drug Administration approves Ziextenzo (pegfilgrastim-bmez).  Ziextenzo, a biosimilar of Neulasta, is a long-acting G-CSF indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.  Ziextenzo is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia. Read full press release.


Massachusetts Society of Clinical Oncologists (c) 860 Winter Street, Waltham, MA. 02451

Waltham, MA. 02451

P.O. Box 549154, Waltham, MA, 02451
t: 781.434.7329 | f: 781.464.4896 |email: nstrunk@mms.org
Powered by Wild Apricot Membership Software